Skip to content

    Amneal Pharmaceuticals (AMRX) stock price & financials

    View AMRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+87.4% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $702.47M
    $730.52M
    $695.42M
    $724.51M
    $784.51M
    +11.7%
    $814.32M
    +11.5%
    $722.52M
    +3.9%
    $796.20M
    +9.9%
    Strengthening
    Operating Profit
    $88.81M
    $75.79M
    $100.35M
    $111.37M
    $70.34M
    -20.8%
    $112.03M
    +47.8%
    $141.77M
    +41.3%
    $129.77M
    +16.5%
    Strengthening
    Net Profit
    -$156.0K
    -$31.08M
    $12.20M
    $22.42M
    $2.37M
    $35.08M
    $62.26M
    +410.5%
    $57.66M
    +157.2%
    Strengthening
    EPS
    $0.00
    $0.04
    $0.07
    $0.01
    $0.20
    +400.0%
    $0.18
    +157.1%
    Strengthening
    Other Income
    -$73.39M
    -$91.11M
    -$62.86M
    -$59.66M
    -$75.57M
    -3.0%
    -$56.80M
    +37.7%
    -$61.60M
    +2.0%
    -$58.78M
    +1.5%
    Strengthening
    Interest
    Depreciation
    Profit before Tax
    $15.42M
    -$15.32M
    $37.49M
    $51.71M
    -$5.22M
    -133.9%
    $55.23M
    $80.18M
    +113.9%
    $70.99M
    +37.3%
    Strengthening
    MarginsOPM
    12.6%
    10.4%
    14.4%
    15.4%
    9.0%
    -29.0%
    13.8%
    +32.6%
    19.6%
    +36.0%
    16.3%
    +6.1%
    Strengthening
    Tax
    23.8%
    -35.4%
    34.3%
    31.1%
    447.2%
    +1781.2%
    10.3%
    2.7%
    -92.1%
    1.9%
    -93.8%
    Weakening
    ReturnsROIC
    0.0%
    7.5%
    -2.9%
    -5.4%
    -0.6%
    -1618.6%
    -8.5%
    -212.9%
    -15.0%
    -410.5%
    -13.9%
    -157.2%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$213.39M$151.20M$341.38M$247.79M$25.98M$91.54M$110.55M$282.03M$127.64M
    Short-Term Investments
    Total Current Assets$1.29B$1.21B$1.55B$1.52B$1.41B$1.38B$1.59B$1.91B$1.95B
    Net PP&E$544.15M$547.87M$536.49M$574.53M$525.94M$490.86M$467.26M$497.00M$456.88M
    Goodwill$426.23M$419.50M$522.81M$593.02M$598.85M$598.63M$597.44M$595.47M$593.50M
    Intangibles$1.65B$1.38B$1.30B$1.17B$1.10B$890.42M$732.38M$563.50M$587.83M
    Total Assets$4.35B$3.67B$4.01B$3.94B$3.80B$3.47B$3.50B$3.68B$3.78B
    LiabilitiesTotal Current Liabilities$553.85M$550.41M$676.90M$677.24M$752.80M$846.60M$1.13B$881.63M$883.19M
    Short-Term Debt$21.45M$21.48M$44.23M$30.61M$29.96M$34.13M$224.21M$6.76M$5.96M
    Long-Term Debt$2.63B$2.61B$2.74B$2.68B$2.59B$2.39B$2.16B$2.57B$2.56B
    Long-Term Leases
    Total Liabilities$3.46B$3.32B$3.66B$3.57B$3.62B$3.45B$3.61B$3.75B$3.74B
    EquityCommon Stock & APIC
    Retained Earnings-$20.92M-$377.88M-$286.82M-$276.20M-$406.18M-$490.18M-$607.06M-$535.00M-$415.09M
    Total Equity$504.75M$232.01M$303.27M$360.34M$298.42M$19.78M-$109.27M-$70.79M$33.02M
    HighlightsNet Cash / (Debt)-$2.44B-$2.48B-$2.44B-$2.46B-$2.60B-$2.33B-$2.28B-$2.29B-$2.44B

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$250.23M$1.71M$379.00M$241.82M$65.10M$345.58M$295.10M$339.99M$200.78M
    Cash from Investing-$396.38M-$19.58M-$317.55M-$194.18M-$174.31M-$69.19M-$63.00M-$112.26M-$212.37M
    Cash from Financing$287.68M-$45.83M$131.81M-$138.12M-$106.62M-$212.57M-$211.79M-$31.53M$69.63M
    SummaryCapital Expenditure-$83.09M-$47.18M-$56.45M-$47.73M-$46.41M-$43.22M-$51.92M-$70.06M-$72.94M
    Free Cash Flow$167.14M-$45.48M$322.56M$194.09M$18.69M$302.36M$243.18M$269.93M$127.83M
    FCF Margin10.1%-2.8%16.2%9.3%0.8%12.6%8.7%8.9%4.1%

    Ratios